The other reason for the price rise can be attributed to Replit’s effort-based pricing, rolled out in July, which calculates ...
Explore Replimune Group stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REPL. Replimune stock falls as FDA denies skin cancer drug approval and investors sue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback